ARWR Quote, Financials, Valuation and Earnings

Celcuity, Inc. has a net margin of 6.29% compared to Arrowhead Pharmaceuticals, Inc.'s net margin of --. Arrowhead Pharmaceuticals, Inc.'s return on equity of 7.7% beat Celcuity, Inc.'s return on equity of -158.5%.

Arrowhead Pharmaceuticals, Inc. has a consensus price target of $67.50, signalling downside risk potential of -4.68%. On the other hand Celcuity, Inc. has an analysts' consensus of $110.50 which suggests that it could grow by 5.22%. Given that Celcuity, Inc. has higher upside potential than Arrowhead Pharmaceuticals, Inc., analysts believe Celcuity, Inc. is more attractive than Arrowhead Pharmaceuticals, Inc..

Arrowhead Pharmaceuticals, Inc. has a beta of 1.209, which suggesting that the stock is 20.893% more volatile than S&P 500. In comparison Celcuity, Inc. has a beta of 0.254, suggesting its less volatile than the S&P 500 by 74.611%.

Arrowhead Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Celcuity, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arrowhead Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Celcuity, Inc. pays out -- of its earnings as a dividend.

Arrowhead Pharmaceuticals, Inc. quarterly revenues are $256.5M, which are larger than Celcuity, Inc. quarterly revenues of --. Arrowhead Pharmaceuticals, Inc.'s net income of $16.1M is higher than Celcuity, Inc.'s net income of -$43.8M. Notably, Arrowhead Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Celcuity, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arrowhead Pharmaceuticals, Inc. is 11.40x versus -- for Celcuity, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Cogent Biosciences, Inc. has a net margin of 6.29% compared to Arrowhead Pharmaceuticals, Inc.'s net margin of --. Arrowhead Pharmaceuticals, Inc.'s return on equity of 7.7% beat Cogent Biosciences, Inc.'s return on equity of -117.99%.

Arrowhead Pharmaceuticals, Inc. has a consensus price target of $67.50, signalling downside risk potential of -4.68%. On the other hand Cogent Biosciences, Inc. has an analysts' consensus of $49.36 which suggests that it could grow by 41.93%. Given that Cogent Biosciences, Inc. has higher upside potential than Arrowhead Pharmaceuticals, Inc., analysts believe Cogent Biosciences, Inc. is more attractive than Arrowhead Pharmaceuticals, Inc..

Arrowhead Pharmaceuticals, Inc. has a beta of 1.209, which suggesting that the stock is 20.893% more volatile than S&P 500. In comparison Cogent Biosciences, Inc. has a beta of 0.504, suggesting its less volatile than the S&P 500 by 49.585%.

Arrowhead Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cogent Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arrowhead Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Cogent Biosciences, Inc. pays out -- of its earnings as a dividend.

Arrowhead Pharmaceuticals, Inc. quarterly revenues are $256.5M, which are larger than Cogent Biosciences, Inc. quarterly revenues of --. Arrowhead Pharmaceuticals, Inc.'s net income of $16.1M is higher than Cogent Biosciences, Inc.'s net income of -$80.9M. Notably, Arrowhead Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Cogent Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arrowhead Pharmaceuticals, Inc. is 11.40x versus 55.99x for Cogent Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ionis Pharmaceuticals, Inc. has a net margin of 6.29% compared to Arrowhead Pharmaceuticals, Inc.'s net margin of -82.06%. Arrowhead Pharmaceuticals, Inc.'s return on equity of 7.7% beat Ionis Pharmaceuticals, Inc.'s return on equity of -43.01%.

Arrowhead Pharmaceuticals, Inc. has a consensus price target of $67.50, signalling downside risk potential of -4.68%. On the other hand Ionis Pharmaceuticals, Inc. has an analysts' consensus of $88.81 which suggests that it could grow by 8.98%. Given that Ionis Pharmaceuticals, Inc. has higher upside potential than Arrowhead Pharmaceuticals, Inc., analysts believe Ionis Pharmaceuticals, Inc. is more attractive than Arrowhead Pharmaceuticals, Inc..

Arrowhead Pharmaceuticals, Inc. has a beta of 1.209, which suggesting that the stock is 20.893% more volatile than S&P 500. In comparison Ionis Pharmaceuticals, Inc. has a beta of 0.278, suggesting its less volatile than the S&P 500 by 72.158%.

Arrowhead Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arrowhead Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Ionis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Arrowhead Pharmaceuticals, Inc. quarterly revenues are $256.5M, which are larger than Ionis Pharmaceuticals, Inc. quarterly revenues of $156.7M. Arrowhead Pharmaceuticals, Inc.'s net income of $16.1M is higher than Ionis Pharmaceuticals, Inc.'s net income of -$128.6M. Notably, Arrowhead Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Ionis Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arrowhead Pharmaceuticals, Inc. is 11.40x versus 13.87x for Ionis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics, Inc. has a net margin of 6.29% compared to Arrowhead Pharmaceuticals, Inc.'s net margin of -45.06%. Arrowhead Pharmaceuticals, Inc.'s return on equity of 7.7% beat Sarepta Therapeutics, Inc.'s return on equity of -20.67%.

Arrowhead Pharmaceuticals, Inc. has a consensus price target of $67.50, signalling downside risk potential of -4.68%. On the other hand Sarepta Therapeutics, Inc. has an analysts' consensus of $20.61 which suggests that it could fall by -7.79%. Given that Sarepta Therapeutics, Inc. has more downside risk than Arrowhead Pharmaceuticals, Inc., analysts believe Arrowhead Pharmaceuticals, Inc. is more attractive than Sarepta Therapeutics, Inc..

Arrowhead Pharmaceuticals, Inc. has a beta of 1.209, which suggesting that the stock is 20.893% more volatile than S&P 500. In comparison Sarepta Therapeutics, Inc. has a beta of 0.485, suggesting its less volatile than the S&P 500 by 51.536%.

Arrowhead Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arrowhead Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Sarepta Therapeutics, Inc. pays out -- of its earnings as a dividend.

Arrowhead Pharmaceuticals, Inc. quarterly revenues are $256.5M, which are smaller than Sarepta Therapeutics, Inc. quarterly revenues of $399.4M. Arrowhead Pharmaceuticals, Inc.'s net income of $16.1M is higher than Sarepta Therapeutics, Inc.'s net income of -$179.9M. Notably, Arrowhead Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Sarepta Therapeutics, Inc.'s PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arrowhead Pharmaceuticals, Inc. is 11.40x versus 0.96x for Sarepta Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.